ACDF Brief comments: The evolving role of SGLT2 inhibitors

ACDF Brief comments The evolving role of SGLT inhibitors
3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof Mark Cooper, Melbourne, Australia - Asian Cardio Diabetes Forum 2019
  • Overview

    Expert faculty provide brief commentaries on content related to the Asian Cardio Diabetes Forum 2019

  • Faculty

    Mark Cooper, MD, Head of Diabetes Department in the Central Clinical School, Monash University, Melbourne, Australia

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    The Asian Cardio Diabetes Forum was funded by Boehringer Ingelheim Singapore

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free